Retatrutide is often nicknamed “GLP-3” online, but its actual description is a triple hormone receptor agonist. The three targets are GIP, GLP-1 and glucagon receptors. It is not a newly numbered GLP hormone, and “triple” does not mean three separate peptides mixed into one pen. Lilly's explanation identifies the molecule and its targets. For readers comparing Retatrutide in Bali, Indonesia, separate evidence about a molecule from the identity and instructions of the finished product.
One molecule, three receptor targets
A receptor agonist activates a receptor. The name describes where a molecule can act; it does not count the number of ingredients on a product label.
| Term | What it describes |
|---|---|
| GLP-1 receptor | One of retatrutide's three receptor targets |
| GIP receptor | A second target, also relevant to tirzepatide |
| Glucagon receptor | The additional target in retatrutide's triple-agonist description |
| Peptide blend | A formulation listing two or more separate ingredients |
That distinction also explains why a blend and a multi-receptor agonist are not two names for the same type of product.
Why the nickname can confuse a product search
Someone searching “GLP-3 pen” may mean retatrutide, a supposed next generation of weight-loss medicine or simply a product marketed with that phrase. Those searches do not guarantee that every result contains the same ingredient.
Use the full compound name when checking a listing and its documents. “Retatrutide,” “triple agonist” and a specific total-content amount together provide more information than a nickname alone. A marketing label should not replace the ingredient identity.
How it differs from tirzepatide
Tirzepatide has GIP and GLP-1 receptor activity. Retatrutide adds glucagon-receptor activity to its target profile. The original tirzepatide development report describes the dual-agonist molecule.
Counting targets does not, by itself, predict a person's response or establish which treatment is appropriate. The receptor description explains the biological design. Clinical studies assess outcomes in particular populations using particular preparations.
The same logic applies to a two-ingredient catalog blend. Two ingredients are not automatically two complementary clinical effects, and three receptor targets are not three times the benefit.
What to check on a Peptides in Bali listing
The Retatrutide page identifies a 32 mg pen. The Tirzepatide page offers 30 mg and 60 mg formats. These numbers describe total labelled contents, not a conversion between the two molecules.
If a seller uses “GLP-3,” ask for the exact ingredient name and applicable documentation. That resolves the naming question more effectively than comparing slogans. Retatrutide remains investigational; a familiar nickname does not change its status or establish that a retail product matches the clinical-trial preparation.
Connect the evidence to a product question in Bali
Read the study’s formulation, route, participants and measured outcome before applying a headline to a product choice. A mechanism explains a research question; it does not establish a result for every finished pen. Keep the exact catalogue presentation beside the evidence, and identify any missing product-specific information before deciding what to ask next.
Product formats to compare in Bali
Compare the following catalogue entries with the product or route discussed above. The stated amount is the total labelled pack content, not a dose or a promise of how long it will last.
| Catalogue product | Labelled contents | What to distinguish |
|---|---|---|
| Retatrutide | 32 mg / pen | Investigational molecule; compare finished-product identity and documents. |
Confirm your Bali order
For Canggu, Berawa, Pererenan, Umalas, Seminyak or Uluwatu, send the exact product, quantity and destination. Ask the team to confirm the delivery arrangements for that address before relying on a proposed time.
View all pen formats · Ask about the exact product on WhatsApp